
Opinion|Videos|December 11, 2024
Pruritus Control With PPAR Agonists in PBC
Key Takeaways
- Pruritus affects over 80% of PBC patients, impacting quality of life and treatment adherence. Effective management is essential for improving patient outcomes.
- Addressing pruritus involves pharmacological treatments and lifestyle changes, tailored to individual patient needs, to alleviate symptoms and enhance well-being.
The panel of experts discuss the role of effectively treating pruritus, a common and debilitating symptom in over 80% of patients with cholestatic liver diseases like primary biliary cholangitis (PBC), and its importance in the long-term management of the disease.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Pruritus is a debilitating symptom experienced by over 80% of patients with cholestatic liver diseases, such as PBC. What is the role of effectively treating pruritus in the long-term management of PBC?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
APPs on the Frontline of AATD Management, With Sarah Tomashefski, MSN
2
Positioning New Agents and Overcoming Real-World Barriers for Asthma and COPD
3
Phase 3 Data Indicate Roflumilast Cream Benefit Extend to Youngest Atopic Dermatitis Patients
4
RAD 2026: Tralokinumab Improves Hand AD Outcomes, Outperforms Dupilumab in MAIC
5




























































